Obsessive-Compulsive Disorder News

Significant dose-response associations were found for transcranial magnetic stimulation and transcranial direct current stimulation across several mental disorders, including schizophrenia and depression, according to research.

Body dysmorphic disorder and appearance preoccupation were relatively common among youth, especially adolescent girls, according to a study published in Journal of the American Academy of Child & Adolescent Psychiatry.

Maternal obsessive-compulsive disorder was associated with increased adverse pregnancy, delivery and neonatal outcomes, according to findings from two cohort studies published in JAMA Network Open.

The FDA has granted 510(k) clearance to Neuronetics Inc. for its obsessive-compulsive disorder motor threshold cap technology for NeuroStar Advanced Therapy for Mental Health.

MIAMI BEACH, Fla. —Treatment with psilocybin significantly reduced symptoms at 8 weeks in patients with severe obsessive-compulsive disorder, according to a poster at the American Society of Clinical Psychopharmacology annual meeting.

HHS has released its “Roadmap for Behavioral Health Integration,” which details policy solutions to help integrate mental health and substance use care into large health care systems.

McLean Hospital in Belmont, Massachusetts, has been named the top hospital in the United States for psychiatric care by the U.S. News & World Report for 2022 to 2023.

The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.

Exposure and response prevention treatment through video teletherapy showed effectiveness in reducing obsessive-compulsive symptoms while improving quality of life, per a study published in the Journal of Medical Internet Research.